Which treatment do I need?

Every year approximately 500,000 new colorectal cancer patients are diagnosed in Europe. The disease begins as benign growths known as a polyp. Over a period of years some of these polyps may progress to cancer. There are several, histological forms of colorectal cancer but by far the most common is adenocarcinoma.

Cancer Stage and Treatment Options

The staging of your cancer refers to how far it has spread beyond the location where it first developed. The stages begin at 0 and go up to Stage IV—the higher the number, the further the cancer has advanced. For example, Stage IV represents metastatic spread to other organs.

The mainstay of treatment is surgery. Patients with cancers that have not spread beyond the colon or to the lymph nodes generally do not require any form of medical treatment or radiotherapy. Patients with more advanced disease often need preoperative chemotherapy, postoperative chemotherapy or chemotherapy as the only treatment.

Recommended chemotherapy regimens are listed in international guidelines. For colorectal cancer patients the most widely used drugs are Fluorouracil (5-FU) plus Leucovorin. Addition of Irinotecan or Oxaliplatin improve the efficacy of 5-FU based therapy but often at the price of side effects. Monoclonal antibodies like Cetuximab, Panitumumab and Bevacizumab are also often used in commonly added to chemotherapy.

IndiTreat®: Individual treatment identification method

IndiTreat was developed initially for colorectal carcinoma (colonic cancer) and assists the doctor in choosing the most effective medical therapy for the patient. In order to perform the IndiTreat® test a small tissue sample is taken from the tumor. This tissue sample contains living tumor cells and is placed in a 2cureX transport container and shipped within 24 hours by courier to the nearest 2cureX laboratory.

From the tumor tissue three-dimensional microtumors consisting of approximately 300 cancer cells are produced. The 3D-microtumors are classified as sensitive or resistant to each available drug depending on whether they continue to grow or perish after the addition of drugs. Clinical studies have documented that the response of the microtumors to the drug treatment in the laboratory is comparable to the response of the patient´s tumor whether the prediction is resistance or sensitivity.